Allegra Sales Slowdown Illustrates Shrinking Rx Allergy Market
This article was originally published in The Tan Sheet
Executive Summary
The closing of the Sanofi-Aventis merger - coupled with another consecutive quarter of declining Allegra (fexofenadine) sales - could accelerate a decision on whether to license out marketing rights to the prescription antihistamine
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning